Abstract: Electrically conductive polymeric composite materials include microbially produced protein nanowires. The conductive composites are useful in diverse electronic materials applications, particularly in applications requiring biocompatibility, such as sensors and wearable electronics.

Abstract: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).

Abstract: A heating element composite comprises a substrate of one or more fibers or threads and an electrically-conductive polymer coating comprising an electrically-conductive polymer material deposited onto the one or more fibers or threads. A thickness of the electrically-conductive polymer coating is at least about 100 nanometers and the electrically-conductive polymer coating covers at least about 75% of an external surface area of the one or more fibers or threads of the substrate. The resulting heating element composite has a sheet resistance of from about 2?/? to about 200?/?.

Abstract: This disclosure relates to novel modified oligonucleotides. Novel modified siRNA are also provided.

Abstract: In an aspect, a method of making a composite comprises mixing titanium dioxide in a aqueous solution comprising an acid to form a titanium dioxide mixture; mixing an aniline monomer and an oxidizing agent with the titanium dioxide mixture to form a reaction mixture; and polymerizing the aniline monomer to form the composite comprising polyaniline and the titanium dioxide; wherein the titanium dioxide has an average particle size of 0.5 to 100 nm; and wherein the acid is free of a (C8+ alkyl) benzene sulfonic acid or a derivative thereof. In another aspect, a composite comprises a plurality of titanium dioxide having an average particle size of 0.5 to 100 nm; a polyaniline; at least one of hydrochloric acid or 2-acryamido-2-propanesulfonic acid or a derivative thereof; wherein the composite is free of a (C8+ alkyl) benzene sulfonic acid or a derivative thereof.

Abstract: Methods of treating wounds in a subject using one or both of a DNA methyltransferase 1 (DNMT1) inhibitor or a nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) inhibitor, and compositions for use in these methods.

Abstract: The invention provides methods for using virus-like particle (VLP) vaccines containing a stabilized pre-fusion respiratory syncytial virus (RSV) F protein to stimulate RSV neutralizing antibodies in pre-immune subjects.

Abstract: The communication system as described herein includes an input feed, a source, and a tuner device. The input feed receives an input signal. The source emits a wireless signal based on the received input signal. The tuner device is disposed adjacent to the source emitting the wireless signal. The tuner device receives the wireless signal emitted from the source and produces a wireless output. In one embodiment, the tunable device includes multiple individually controlled window regions to control a radiation pattern of the wireless output transmitted from the tuner device.

Abstract: Aspects of the disclosure relate to isolated nucleic acids encoding one or more inhibitory nucleic acids. In some embodiments, the inhibitory nucleic acids are microRNAs (miRNAs) or artificial microRNAs (amiRNAs). The inhibitory nucleic acids may target one or more genes involved in cytochrome p450 toxicity, for example Slc16a2, Acls5, and Cyb5b. In some embodiments, an inhibitory nucleic acid is a miR-375. The disclosure relates, in some aspects, to methods of reducing cytochrome p450-related toxicity in a cell (e.g., a liver cell) by administering the isolated nucleic acids of the disclosure.

Abstract: Aspects of the disclosure relate to compositions (e.g., isolated nucleic acids, rAAV vectors, rAAVs, etc.) and methods for gene editing. The disclosure is based, in part, on isolated nucleic acids encoding combinations of gene editing proteins (e.g., Cas proteins) and base editors (e.g., Adenosine Deaminase Acting on RNA deaminase domains) with certain regulatory sequences that are amenable to packaging in recombinant adeno-associated viruses (rAAVs). In some embodiments, compositions described by the disclosure are useful for treating certain diseases in a subject in need thereof.

Abstract: A method for processing formulae includes encoding a formula by: training, with a server, a model by using a machine learning algorithm with a data set that includes a plurality of formulae; transforming, with a processor, a first formula into a tree format using the trained model; converting, with the processor, the tree format of the first formula into a plurality of lists; and encoding, with the processor, the plurality of lists into a fixed dimension vector by leveraging a stacked attention module; and generating one or more formula candidates by: obtaining, with the processor, input information; and generating, with the processor, one or more second formula candidates based on input information by using the stacked attention module with a tree beam search algorithm.

Abstract: Aspects of the disclosure relate to compositions and methods for expressing anti-Vascular endothelial cell growth factor (VEGF) agent in a cell or subject. In some embodiments, the disclosure provides rAAVs comprising a capsid protein (e.g., AAV2 variants, AAV2/3 hybrid variants, AAV8 variants, etc.), and a transgene encoding an anti-VEGF agent (e.g., KH902) and one or more regulatory sequences. In some embodiments, compositions described herein are useful for treating subjects having diseases associated with angiogenesis or aberrant VEGF activity/signaling.

Abstract: The present invention relates to the construction of, and immunization with viral vaccines. In particular, bivalent vaccines that are capable of providing simultaneous virus infection protection for two or more different viruses. Furthermore, the bivalent vaccines contemplated herein are contemplated as being effective in a neonatal mammal. One such bivalent viral vaccine comprises two antigenic epitopes against the dengue viruses and at least one antigenic epitope against hepatitis B virus. Immunization cross-reactivity may also provide infection protection against other viruses as well.

Abstract: Methods of treating or reducing the risk of obesity and/or obesity-related disorders, e.g., metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes, using C20orf27 proteins or nucleic acids.

Abstract: Systems and methods are provided for trapping and electrically monitoring molecules in a nanopore sensor. The nanopore sensor comprises a support structure with a first and a second fluidic chamber, at least one nanopore fluidically connected to the two chambers, and a protein shuttle. The protein shuttle comprises an electrically charged protein molecule, such as Avidin. The nanopore can be a Clytosolin A. A method can comprise applying a voltage across the nanopores to draw protein shuttles towards the nanopores. The ionic current through each or all of the nanopores can be concurrently measured. Based on the measured ionic current, blockage events can be detected. Each blockage event indicates a capture of a protein shuttle by at least one nanopore. Each blockage event can be detected through a change of the total ionic current flow or a change in the ionic current flow for a particular nanopore.

Abstract: The disclosure, in some aspects, relates to nucleic acids, compositions and kits useful for gene therapy with reduced immune response to transgene products.

Abstract: The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders.

Abstract: The present invention relates generally to genetically modified non-human animals and immunodeficient non-human animals characterized by restored complement-dependent cytotoxicity, as well as methods and compositions for assessment of therapeutic antibodies in the genetically modified immunodeficient non-human animals. In specific aspects, the present invention relates to immunodeficient non-obese diabetic (NOD), A/J, A/He, AKR, DBA/2, NZB/B1N, B10.D2/oSn and other mouse strains genetically modified to restore complement-dependent cytotoxicity which is lacking in the unmodified immunodeficient mice. In further specific aspects, the present invention relates to NOD.Cg-Prkdcscid IL2retmlWjl/SzJ (NSG), NOD.Cg-Rag1tm1Mom Il2rgtmlWjl/SzJ (NRG) and NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mice genetically modified to restore complement-dependent cytotoxicity which is lacking in unmodified NSG, NRG and NOG mice.

Abstract: A system and method for memory allocation and management in non-uniform memory access (“NUMA”) architecture computing environments is disclosed. The system and method contemplates both hardware heterogeneity and allocation/deallocation attributes, with fine-grained memory management. NUMAlloc is centered on a binding-based memory management. On top of it, NUMAlloc proposes an “origin-aware memory management” to ensure the locality of memory allocations and deallocations, as well as a method called “incremental sharing” to balance the performance benefits and memory overhead of using transparent huge pages. It further introduced an interleaved heap to reduce the load imbalance among different nodes and an efficient mechanism for object movement. The system and method provides a scalable and increased performance alternative over other prior art memory allocators.

Abstract: A NOD.Cg-PrkdcscidH2rgtm1 Wjl/SzJ.(NOD-scid-IL2r?null, NSG) mouse which is genetically modified such that the en NSG mouse lacks functional major histocompatibility complex I (MHC I) and lacks functional major histocompatibility complex II (MHC II) is provided according to aspects of the present, invention. According to specific aspects the genetically modified NSG mouse, is a NOD.Cg-PrkdcscidH2-K1tml Bpe H2-Ab1eml Mvw H2-D1tml Bpe H2rgtm Wjl/SzJ (NSG-Kb Db)null(IAnull)) mouse, NSG-RIP-DTR (Kb Db)null(IAnull) mouse, or a NOD.Cg-B2mtmlUnePrKdcscidH2dlAb1-E?H2rgtm1 Wjl/SzJ (NSG-B2Mnull(IA IEnull)) mouse. Human, immune cells and/or human: tumor cells are administered to a genetically modified immunodeficient mouse according to aspects described herein and assays of one or more test substances can be performed using the provided mice.